Multiple Sclerosis Centers Revise MRI Guidelines

Until more is known about gadolinium-based contrast agents, the FDA recommends that individuals with MS talk with their healthcare professionals about their medical conditions, as well as any symptoms or severe problems that they may be experiencing. Furthermore, they should report any side effects related to GBCAs, as well as have any questions/concerns about GBCAs with MRI scans addressed. The FDA also recommends that healthcare professionals consider the features of each agent in an effort to avoid gadolinium retention in patients. They also recommend limiting the use of GBCAs in situations where they are not medically necessary and they urge the revision of repetitive use of GBCAs according to standard treatment protocols.